Customized Monoclonal Antibody Design Highlighted at the AACC Clinical Lab Expo

Biotech researchers and other life scientists working with monoclonal antibodies (MABs) who are attending the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013, are invited to learn how to exploit the services of an innovative developer and producer of custom-made recombinant antibodies.

Medix Biochemica (Kauniainen, Finland), producer of monoclonal antibodies for the global IVD industry and of proprietary rapid diagnostic tests, is highlighting its MedixMAB by Design antibody production service at the Clinical Lab Expo.


By offering a completely customized service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design paves the way for the development of superior IVD assays. Antibodies are produced to the strictest international quality standards, and this new service gives IVD manufacturers access to topflight biological without the need to invest in costly production facilities and expertise.

Medix makes monoclonal antibodies using an advanced in vitro system, which incorporates the latest in cutting-edge phage display-production technology. These antibodies can target a broad range of antigens, including poorly immunoreactive and toxic compounds. Successful recombinant antibodies can then easily be produced in bulk quantities. Alternatively, Fab fragments, which greatly enhance specificity and sensitivity of solid-phase IVD assays, can be generated in just three months. All development and manufacturing processes are comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and [US] FDA QSR quality standards.

Maija Partanen, product manager for MedixMAB by Design, said, “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”

Related Links:
Medix Biochemica